Helix BioPharma Corp. (HBPCF)
OTCMKTS
· Delayed Price · Currency is USD
1.734
+1.134 (189.00%)
At close: Oct 22, 2025
Helix BioPharma Balance Sheet
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | 2016 - 2020 |
| Cash & Equivalents | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 | Upgrade
|
| Cash & Short-Term Investments | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 | Upgrade
|
| Cash Growth | -93.99% | 33.79% | -75.15% | -8.78% | -15.82% | Upgrade
|
| Other Receivables | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 | Upgrade
|
| Receivables | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 | Upgrade
|
| Prepaid Expenses | 0.22 | 0.32 | 0.13 | 0.16 | 0.1 | Upgrade
|
| Total Current Assets | 0.41 | 1.46 | 1 | 3.7 | 4.02 | Upgrade
|
| Property, Plant & Equipment | 0 | 0.03 | 0.03 | 0.04 | 0.05 | Upgrade
|
| Other Intangible Assets | 18.39 | 0 | - | - | - | Upgrade
|
| Total Assets | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 | Upgrade
|
| Accounts Payable | 2.3 | 0.86 | 0.49 | 0.6 | 1.47 | Upgrade
|
| Accrued Expenses | 0.58 | 0.72 | 0.38 | 0.35 | 0.38 | Upgrade
|
| Short-Term Debt | 0.34 | - | - | - | - | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 2.47 | 2.03 | Upgrade
|
| Other Current Liabilities | - | - | 1 | -0 | - | Upgrade
|
| Total Current Liabilities | 3.22 | 1.58 | 1.87 | 3.41 | 3.87 | Upgrade
|
| Long-Term Debt | - | - | - | - | 1.58 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0 | - | Upgrade
|
| Total Liabilities | 3.22 | 1.58 | 1.87 | 3.41 | 5.46 | Upgrade
|
| Common Stock | 179.29 | 158.57 | 152.07 | 147.51 | 139.66 | Upgrade
|
| Additional Paid-In Capital | 48.3 | 47.36 | 44.14 | 37.59 | 27.87 | Upgrade
|
| Retained Earnings | -215.88 | -210.67 | -201.41 | -195.12 | -188.55 | Upgrade
|
| Comprehensive Income & Other | 3.87 | 4.65 | 4.36 | 10.34 | 19.63 | Upgrade
|
| Total Common Equity | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade
|
| Shareholders' Equity | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade
|
| Total Liabilities & Equity | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 | Upgrade
|
| Total Debt | 0.34 | - | - | 2.47 | 3.61 | Upgrade
|
| Net Cash (Debt) | -0.27 | 1.08 | 0.81 | 0.78 | -0.05 | Upgrade
|
| Net Cash Growth | - | 33.79% | 3.06% | - | - | Upgrade
|
| Net Cash Per Share | -0.00 | 0.02 | 0.02 | 0.03 | -0.00 | Upgrade
|
| Filing Date Shares Outstanding | 76.38 | 49.02 | 43.33 | 34.86 | 28.49 | Upgrade
|
| Total Common Shares Outstanding | 74.16 | 49.02 | 40 | 34.36 | 28.23 | Upgrade
|
| Working Capital | -2.81 | -0.12 | -0.88 | 0.28 | 0.14 | Upgrade
|
| Book Value Per Share | 0.21 | -0.00 | -0.02 | 0.01 | -0.05 | Upgrade
|
| Tangible Book Value | -2.8 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade
|
| Tangible Book Value Per Share | -0.04 | -0.00 | -0.02 | 0.01 | -0.05 | Upgrade
|
| Machinery | 1.22 | 1.46 | 1.44 | 1.44 | 1.43 | Upgrade
|
| Leasehold Improvements | - | 0.36 | 0.36 | 0.36 | 0.36 | Upgrade
|
Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.